P. B. M. W. M. TIMMERMANS^{*}, F. KARAMAT ALI, S. P. KOSSEN, P. A. VAN ZWIETEN, Department of Pharmacy, Division of Pharmacotherapy, University of Amsterdam, Plantage Muidergracht 24, 1018 TV Amsterdam, The Netherlands

The interaction between clonidine and histamine H_2 -receptor antagonists has indicated that histamine H_2 -receptors are involved in the central hypotensive response to clonidine (Finch et al 1978; Karppanen et al 1976, 1977). A recent study by Pilc et al (1979) demonstrated that in very high concentrations only histamine H_3 -receptor agonists and antagonists displaced [³H]-clonidine from its specific (α_2) binding sites in membranes from rat cerebral cortex. This finding makes its unlikely that central α_2 - as well as histamine H_2 -receptors are the common sites of interaction.

[³H]Prazosin labels α_1 -adrenoceptors in the rat brain with extreme selectivity (Greengrass & Bremner 1979). Since the drug also interferes with the central hypotensive effect of clonidine (Timmermans et al 1979) we studied the displacement of [³H]prazosin from α_1 adrenoceptor sites in rat brain membranes by the histamine H₂-receptor antagonists metiamide and cimetidine.

Fresh brains (minus cerebella) of male Wistar rats (190-220 g) were homogenized in 20 vol (w/v) ice-cold 50 mM Tris/HCl buffer (pH 7·7 at 25 °C). The homogenate was centrifuged twice (50 000 g; 10 min; 4 °C) with resuspension of the pellet in fresh buffer between spins. The final pellet was homogenized in Tris/HCl buffer (1 mg protein per 1 ml). Aliquots (500 μ l) were incubated at 25 °C for 60 min with [³H]prazosin (spec. act. 33 Ci mmol⁻¹; 0·05-10 nM) and various concentrations of drugs in a final volume of 1 ml and terminated by rapid filtration through Whatman GF/B filters followed by three 5 ml washes of ice-cold Tris/HCl




FIG. 1. Displacement of [^aH]prazosin (0.2 nM) from its specific binding sites in rat cerebral membranes by increasing concentrations of unlabelled prazosin (\bigoplus), diphenhydramine(\triangle), metiamide(\square) and cimetidine(\blacksquare). Symbols represent mean values out of four separate experiments (s.e.m. < 10%).

• Correspondence.

buffer. Filters were counted in Instagel at 35-40% efficiency. Specific binding was defined as the excess over blanks containing $2.0 \ \mu M$ phentolamine.

In accordance with the results reported by Greengrass & Bremner (1979) the specific binding of [³H]prazosin was saturable and of high affinity. Scatchard analysis indicated a single population of binding sites ($K_D = 0.2 \text{ nM}$; $B_{max} = 140 \text{ fmol mg}^{-1}$ protein). [³H]Prazosin (0.2 nM) was specifically displaced by non-radioactive prazosin (IC50 = 0.6 nM) (Fig. 1).

Clonidine itself also proved a reasonably potent inhibitor of [³H]prazosin binding (IC50 = 1.2μ M). This finding lends support to the pharmacological interaction established between these two drugs (Timmermans et al 1979). The histamine H₂-receptor antagonists metiamide and cimetidine were very weak in competing for [3H]prazosin binding. Displacement occurred at high concentrations only. In contrast, the histamine H₁receptor antagonist diphenhydramine, which does not reduce the central hypotensive effect of clonidine (Karppanen et al 1976), was more active in inhibiting [³H]prazosin binding (IC50 = 5.2μ M). This may be explained by the moderate a-adrenoceptor antagonist activity of this drug. The present results show the absence of a significant affinity of histamine H₂receptor antagonists for specific binding sites in rat cerebral membranes labelled by [3H]prazosin (a1adrenoceptors). This finding and those of Pilc et al (1979) indicate that neither central α_1 - nor α_2 -adrenoceptors represent the targets for histamine H₂-receptor antagonists in their antagonism of the central hypotensive effect of clonidine. Moreover, they also reject the hypothesis that clonidine initiates its central hypotensive effect via histamine H2-receptors.

We are greatly indebted to Dr M. J. Davey (Pfizer, Sandwich, Kent) for the generous donation of [³H]prazosin and to Smith, Kline and French (Welwyn Garden City) for the histamine H₂-receptor antagonists. September 18, 1979

REFERENCES

- Finch, L., Harvey, C. A., Hicks, P. E., Owen, D. A. A. (1978) Neuropharmacology 17: 307-313
- Greengrass, P., Bremner, R. (1979) Eur. J. Pharmacol. 55: 323-326
- Karppanen, H., Paakkari, I., Paakkari, P. (1977) Ibid. 42: 299-302
- Karppanen, H., Paakkari, I., Paakkari, P., Huotari, R., Orma, A.-L. (1976) Nature (London) 259: 587-588
- Pilc, A., Golembiowska-Nikitin, K., Vetulani, J. (1979) Eur. J. Pharmacol. 56: 177–178
- Timmermans, P. B. M. W. M., Lam, E., van Zwieten, P. A. (1979) Ibid. 55: 57-66